According to the new market research report “In situ Hybridization Market by Technique (FISH, CISH), Application (Cancer Diagnosis, Neuroscience, Cytology, Infectious Disease), & End User (Molecular Diagnostic Laboratories, Academic And Research Institutions) – Global Forecast to 2021″, published by MarketsandMarkets™, analyzes and studies the major market drivers, restraints/challenges, and opportunities.
In the coming years, the market is expected to witness the highest growth in the Asia-Pacific region. This can be attributed to the growing presence of international players in China and India, increasing cancer prevalence and diagnosis, and increased healthcare expenditure across the Asia-Pacific region are drivers for the in situ hybridization market in this region.
North America is expected to account for the largest share of the global market. This can be attributed to growing clinical and research in cancer by biotechnology and pharmaceutical companies, government initiatives, increasing prevalence and diagnosis of cancer in the U.S. and Canada, and increasing adoption of companion diagnostics. Increased adoption of companion diagnostics is attributed to the development and launch of newer therapeutic agents.
Browse and in-depth TOC on ” In situ Hybridization Market ”
60– Tables
26 – Figures
194 – Pages
View more detailed TOC @ https://www.marketsandmarkets.com/Market-Reports/in-situ-hybridization-market-212028829.html
In the U.S., the in situ hybridization market is driven by increasing government initiatives, growing biomedical research, rising prevalence of cancer, and growing demand for companion diagnostics and personalized medicine. In Canada, the growth of the market is driven by increased government funding and growing prevalence of cancer.
On the basis of technique, the global market is segmented into fluorescent in situ hybridization (FISH) and chromogenic in situ hybridization (CISH). The FISH segment is expected to command the largest share of the global in situ hybridization market, by technique in 2016. This segment is also projected to grow at the highest CAGR during the forecast period (2016-2021). This can be attributed to factors such as like high resolution of this technique, rising adoption in research activities & laboratories to diagnose cancer, chromosomal abnormalities, and infectious diseases, among others.
Avail Discount on Report – https://www.marketsandmarkets.com/discountreports.asp?id=212028829
The in situ hybridization market is projected to reach USD 739.9 Million by 2021 from USD 557.1 Million in 2016, at a CAGR of 5.8% in the next five years (2016 to 2021). Increasing diagnosis and growing incidence & prevalence of cancer, technology advancements in therapeutics, increasing government initiatives globally are expected to drive the growth of the market in the coming years.
The global market is segmented on the basis of technique, application, and end user. By technique, the market is categorized into fluorescent in situ hybridization (FISH) and chromogenic in situ hybridization (CISH). The FISH segment is expected to command the largest share of the global market, by technique in 2016. This segment is also projected to grow at the highest CAGR during the forecast period (2016-2021). This can be attributed to factors such as like high resolution of this technique, rising adoption in research activities & laboratories to diagnose cancer, chromosomal abnormalities, and infectious diseases, among others.
Key Players:
Abbott Laboratories, Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), Leica Biosystems Nussloch GmbH (Germany), Agilent Technologies (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Merck KGaA (Germany), PerkinElmer, Inc. (U.S.), Exiqon A/S (Denmark), BioGenex Laboratories, Inc. (U.S.), Advanced Cell Diagnostics, Inc. (U.S.), and Bio SB Inc. (U.S.) are some of the key players in the in situ hybridization market worldwide.
Click for Adjacent Markets Report Available.
Request for bundle reports: https://www.marketsandmarkets.com/RequestBundleReport.asp?id=212028829
